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1164Background: The progression of carotid intima–media thickness (CIMT) is closely
associatedwith ischemic stroke recurrence. However, the efficacy of cilostazol on pre-
venting CIMT progression in stroke patients has never been investigated properly by
a prospective trial.Methods: This study is a part of ‘‘Trial of Cilostazol in Symptomatic
Intracranial Arterial Stenosis-2.’’ Six centers that are available to measure CIMT ac-
cording to the protocol participated in this substudy. After 7 months of randomiza-
tion, the changes of CIMTwere compared between cilostazol group and clopidogrel
group. CIMTwasmeasured by a semiautomated software (Intimascope) andwas pre-
sented as the mean of maximum (CIMT-max) and average (CIMT-ave) of both com-
mon carotid arteries. Linear logistic regression analysis and analysis of covariance
were performed to verify the independent factors associated with CIMT progression.
Results: Among the 85 patients, 39 subjects were assigned to cilostazol group and 46
subjects to clopidogrel group. Follow-up CIMT significantly decreased in cilostazol
group (CIMT-max:2.036 .11 and CIMT-ave:2.026 .08) comparedwith the increase
in clopidogrel group (CIMT-max: .04 6 .20 and CIMT-ave: .04 6 .11; P 5 .05 and
P5 .04, respectively). Female, diabetes, and smoking were independently associated
with the progression of CIMT, whereas the use of cilostazol was against CIMT pro-
gression from the results of linear regression analysis (P 5 .03 for both CIMT-max
and CIMT-ave). The use of cilostazol also well predicted less progression of CIMT
at follow-up after adjusting for baseline CIMT values and conventional risk factors
(CIMT-max: P 5 .04 and CIMT-ave: P 5 .03). Conclusion: Cilostazol has a beneficial
effect in preventing the progression of CIMT in ischemic stroke patients. Key Words:
Intracranial arterial stenosis—intima–media thickness—atherosclerosis—antiplatelets.
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EFFECT OF CILOSTAZOL ON CIMT 1165Introduction
Increased carotid intima–media thickness (CIMT) is
associated with the risk of ischemic stroke or coronary ar-
tery disease.1 Though CIMT progression in general popu-
lation demonstrated a limited clinical implication on
predicting cardiovascular events,2 ischemic stroke pa-
tients with CIMT progression are still prone to long-term
stroke recurrence.3 CIMT has beenwidely used as a surro-
gate marker of generalized atherosclerosis and an alterna-
tive outcome measure for vascular events in studies that
had investigated the efficacy of lipid-modifying agents
or antiplatelet agents.4
Cilostazol is a selective phosphodiesterase-3 inhibitor
that demonstrated antiproliferative and anti-atherogenic
effects from various clinical trials. Cilostazol prevented
the progression of atherosclerosis in multiple vascular
beds. The restenosis after coronary stenting was less
frequent with the use of cilostazol,5 and it was also effec-
tive for preventing the progression of CIMT in diabetic
patients.6 Recently, we demonstrated that cilostazol is
protective against the progression of symptomatic intra-
cranial atherosclerotic stenosis (ICAS).7 However, the ef-
fect of cilostazol on CIMT progression among ischemic
stroke patients has never been investigated by a well-
organized randomized trial.
Therefore, we have performed this study to investigate
the effect of cilostazol on CIMT progression in symptom-
atic ICAS patients, as a substudy of ‘‘Trial of Cilostazol in
Symptomatic Intracranial Arterial Stenosis’’ (TOSS)-2.7Methods
Study Design
TOSS-2 was a double-blinded randomized controlled
trial that compared the safety and efficacy against the pro-
gression of ICAS between cilostazol plus aspirin and clo-
pidogrel plus aspirin (unique identifier: NCT00130039).
The progression rate of symptomatic ICASwas compared.
Acute ischemic stroke patients aged 35 years or older with
symptomatic ICAS within 2 weeks of symptom onset
were recruited. However, to avoid other etiologies of
intracranial stenosis, subjects suspicious of (1) nonathero-
sclerotic vasculopathy such as arterial dissection or moya-
moya disease, (2) cardioembolism, or (3) significant
proximal artery stenosis were excluded. A detailed
description including the inclusion and exclusion criteria
of the subjects were previously published.7 Among the 20
centers that participated in TOSS-2, 6 centers that are
available to perform carotid ultrasonography were
included. However, the proposal review and accreditation
of the study center delayed the initiation of CIMT sub-
study after the first enrollment of the patient to TOSS-2.
The subjects were randomly assigned either to cilosta-
zol group (aspirin 100 mg plus cilostazol 200 mg, daily)
or clopidogrel group (aspirin 100 mg plus clopidogrel75 mg, daily) for 7 months after an informed consent by
themselves or their next-on-kin. All the participants
received the best medical treatment, which is currently
available, and were strongly recommended for angio-
tensin receptor blocker and statin treatment, according
to the protocol. Demographic characteristics, risk factors
of atherosclerosis, and laboratory data including fasting
glucose, C-reactive protein (CRP), and lipid profiles (total
cholesterol, low-density lipoprotein cholesterol [LDL-C],
high-density lipoprotein cholesterol [HDL-C], apolipo-
protein A1 [Apo A1], and apolipoprotein B [Apo B])
were obtained. Carotid ultrasonography was performed
for the purpose of measuring CIMT according to a stan-
dardized protocol. Sevenmonths after the randomization,
laboratory data (fasting glucose, lipid profiles, and CRP)
and carotid ultrasonography were followed up, and
concomitant medication used during the study period
was also obtained. The protocol was approved by the
ethics committee of each participating center.
Measurement of CIMT
Carotid ultrasonography was performed at each center
by skilled sonographers. A high-resolution linear array
vascular probe (10 MHz) was used to obtain the images
from right and left carotid arteries. CIMT was measured
from the standardized longitudinal B-mode images,
which were obtained from the far wall of each common
carotid artery, extending from 10 to 20 mm proximal to
the tip of bifurcation site according to the Mannheim
carotid intima-media thickness consensus.8 All the
DICOM (digital imaging and communications in medi-
cine) images, which contain the proper CIMT of both
sides, were electronically archived from each center to
the central laboratory for CIMT measurement. To avoid
a possible inter-rater disagreement,9 CIMTwas measured
using dedicated semiautomated software (Intimascope;
Media Cross Co., Tokyo, Japan) by a reader blinded to
all clinical information (S.R.K.). The results of automated
evaluation were presented as the maximum (CIMT-max)
and average (CIMT-ave). CIMT-max was calculated as the
mean of maximal points in both common carotid arteries,
and CIMT-ave represented the mean of average value ob-
tained from 250 computer-based points from each com-
mon carotid artery (Fig 1).
Statistical Analysis
Demographic characteristics and clinical data were
compared between the 2 groups using Student t test, Pear-
son chi-square test, and Fisher exact test appropriately.
The changes of laboratory data and CIMT progression
after 7 months were compared between the 2 groups us-
ing Student t test. For the purpose to identify the factors
independently associated with CIMT progression, multi-
variate linear regression analysis was performed. Factors
with potential association (P , .20) from univariate
Figure 1. Standardized longitudinal B-mode of
common carotid artery (A); automated measure-
ment of intima–media thickness from the far
wall (B); mean of CIMT was obtained from
average of 250 computer-based points (C).
B.J. KIM ET AL.1166analysis were entered to the multivariate analysis. Addi-
tionally, to eliminate a potentially serious source of con-
founding by baseline CIMT on follow-up CIMT, 2
models of univariate analysis of covariance (ANCOVA)
were performed. The baseline CIMT-max and CIMT-ave
was entered as a covariate in each model. Age, gender,
and conventional risk factors including hypertension,
diabetes, dyslipidemia, and smoking were also entered
as a covariate. Statistical analysis was performed using
SPSS 17.0 (SPSS Inc., Chicago, IL).
Results
Among the 223 patients who have participated in
TOSS-2 from the 6 centers that were available for per-
forming carotid ultrasonography, 101 patients received
the baseline carotid ultrasonography and were enrolled.
Ultrasonography was not performed in the remaining
122 patients who were recruited to TOSS-2 before the
initiation of this substudy. Among the enrolled 101
patients, 16 patients did not receive the follow-up carotidFigure 2. Trial profile. Abbreviation: TOSS-2, Trial of Cilostazol in Symp-
tomatic Intracranial Arterial Stenosis-2.ultrasonography. Therefore, 85 patients were finally
included in this substudy. Two patients underwent ca-
rotid ultrasonography only on 1 side because of technical
problems. Thirty-nine patients were assigned to cilostazol
and 46 patients to clopidogrel (Fig 2).
There were no significant differences in demographic
characteristics, atherosclerosis risk factors, concomitant
medication, baseline CIMT, and laboratory results be-
tween the 2 groups (Tables 1 and 2). The subtypes or
dosage of statin also did not differ between the 2 groups
(data not shown). However, after 7 months of treatment,
the level of Apo B decreased more significantly in cilosta-
zol group (214.23 6 26.48 versus 2.51 6 20.08; P 5 .02).
Additionally, the ratio of Apo B/Apo A1 also decreased
more in the cilostazol group (2.18 6 .17 versus
2.05 6 .19; P 5 .004). The decreased level of LDL-C and
CRP and the increased level of HDL-C were greater in
the cilostazol group. However, these findings were not
statistically significant. Finally, CIMT-max and CIMT-
ave decreased in cilostazol group and increased in the clo-
pidogrel group (Table 2). These changes in CIMT-maxTable 1. Subject baseline characteristics
Cilostazol
(n 5 39)
Clopidogrel
(n 5 46) P
Age (y) 66.67 6 11.27 66.13 6 11.03 .83
Male 22 (56.4%) 22 (47.8%) .43
Hypertension 24 (61.5%) 31 (67.4%) .57
Diabetes 14 (35.9%) 14 (30.4%) .59
Hyperlipidemia 19 (48.7%) 16 (34.8%) .19
Smoking 20 (51.3%) 19 (41.3%) .36
Heart disease 3 (7.7%) 1 (2.2%) .23
Concomitant
medication
ARB 17 (43.6%) 13 (28.3%) .14
ACE-I 3 (7.7%) 1 (2.2%) .23
CCB 19 (48.7%) 20 (43.5%) .63
Statin 24 (61.5%) 24 (52.2%) .39
Abbreviations: ARB, angiotensin-II receptor blocker; ACE-I,
angiotensin-converting enzyme inhibitor; CCB, calcium channel
blocker.
Results are expressed as number (column %) or mean 6 SD.
Table 2. Changes in laboratory data and CIMT after treatment
Cilostazol Clopidogrel P
Total cholesterol (mg/dL)
Baseline 191.51 6 43.74 190.24 6 33.94 .80
Follow-up 161.00 6 35.25 167.91 6 33.43 .36
Difference 229.74 6 56.43 222.33 6 44.91 .51
LDL-C (mg/dL)
Baseline 122.00 6 28.89 118.35 6 23.95 .53
Follow-up 93.08 6 28.40 103.57 6 28.55 .10
Difference 229.95 6 38.87 214.78 6 36.41 .07
HDL-C (mg/dL)
Baseline 45.92 6 10.32 43.83 6 10.33 .36
Follow-up 53.14 6 15.24 46.15 6 11.41 .02
Difference 6.88 6 11.85 2.33 6 10.00 .06
Apo A1 (mg/dL)
Baseline 124.40 6 24.88 123.70 6 22.03 .90
Follow-up 144.18 6 25.19 132.86 6 24.39 .04
Difference 17.34 6 22.94 9.59 6 25.45 .19
Apo B (mg/dL)
Baseline 82.64 6 22.58 79.15 6 17.53 .47
Follow-up 68.74 6 19.53 79.25 6 20.03 .02
Difference 214.23 6 26.48 2.51 6 20.08 .02
Apo B/Apo A1 ratio
Baseline .68 6 .18 .66 6 .18 .62
Follow-up .49 6 .15 .61 6 .16 .001
Difference 2.18 6 .17 2.05 6 .19 .004
Fasting glucose (mg/dL)
Baseline 136.84 6 54.90 129.71 6 59.00 .57
Follow-up 110.46 6 28.10 117.07 6 34.92 .35
Difference 224.82 6 47.37 212.20 6 58.74 .29
CRP (mg/dL)
Baseline .52 6 1.20 .49 6 .89 .91
Follow-up .13 6 .17 .35 6 .56 .01
Difference 2.40 6 1.21 2.15 6 .72 .28
CIMT-max (mm)
Baseline 1.00 6 .19 1.00 6 .15 1.00
Follow-up .97 6 .19 1.04 6 .25 .16
Difference 2.03 6 .11 .04 6 .20 .05
CIMT-ave (mm)
Baseline .81 6 .14 .81 6 .11 .92
Follow-up .79 6 .14 .83 6 .17 .20
Difference 2.02 6 .08 .02 6 .11 .04
Abbreviations: Apo, apolipoprotein; CRP, C-reactive protein; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein
cholesterol.
Results are expressed as mean 6 SD. Difference represents the gap between follow-up and baseline of each parameter.
EFFECT OF CILOSTAZOL ON CIMT 1167and CIMT-ave were both statistically significant (P 5 .05
and P 5 .04, respectively).
From the multivariate linear regression analysis, the
progression of CIMT-max and CIMT-ave was indepen-
dently associated with female, diabetes, and smoking.
The use of cilostazol was protective against the progres-
sion of CIMT-max and CIMT-ave even after adjusting
for potential confounders (Tables 3 and 4, respectively).
In each model of ANCOVA, after adjusting for the base-
line CIMT values, demographic factors, and conventional
risk factors relatedwith the progression of atherosclerosis,the statistical significances of cilostazol for predicting
follow-up CIMT-max and CIMT-ave were maintained
(ANCOVA F 5 4.539, P 5 .04; and ANCOVA F 5 4.853;
P 5 .03, respectively). Additionally, follow-up CIMT-
max was independently associated with gender
(F5 8.030, P5 .006), diabetes (F5 7.757, P5 .007), smok-
ing (F 5 6.766, P 5 .01), and baseline CIMT-max
(F5 73.787,P,.001). Also, follow-upCIMT-avewas inde-
pendently associated with gender (F 5 10.691, P 5 .002),
diabetes (F 5 4.781, P 5 .03), smoking (F 5 5.621
P 5 .02), and baseline CIMT-ave (F 5 109.392, P , .001).
Table 3. Independent factors associated with CIMT-max progression
b 95% CI P Adjusted b* Adjusted P*
Age .002 2.002 to .006 .28
Female .138 .041 to .236 .006 .143 .001
Hypertension .052 2.031 to .134 .22
Diabetes .103 .021 to .185 .01 .095 .008
Hyperlipidemia 2.027 2.113 to .059 .53
Smoking .136 .034 to .238 .01 .115 .01
Heart disease .019 2.160 to .198 .83
Cilostazol 2.087 2.166 to .007 .03 2.072 .03
ARB .023 2.061 to .107 .58
ACE-I .045 2.150 to .239 .65
CCB 2.025 2.108 to .058 .55
Statin .014 2.078 to .107 .76
Change of LDL-C .001 2.001 to .001 .99
Change of HDL-C .000 2.002 to .005 .48
Initial CIMT-max 2.088 2.324 to .148 .46
Abbreviations: ACE-I, angiotensin converting enzyme inhibitor; ARB, angiotensin-II receptor blocker; CCB, calcium channel blocker; CI,
confidence interval; CIMT, carotid intima–media thickness; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein
cholesterol.
Factors with potential association (P , .20) from the univariate analysis was entered into the multiple regression analysis.
*Adjusted b and adjusted P represents the results of multivariate analysis.
B.J. KIM ET AL.1168Discussion
This prospective study was designed to verify the effect
of cilostazol on CIMT in symptomatic ICAS patients. Our
results show that cilostazol plus aspirin was more pro-
tective against the progression of CIMT compared with
clopidogrel plus aspirin, before and after adjusting for
conventional risk factors of atherosclerosis progressionTable 4. Independent factors associa
b 95% CI
Age .001 2.001 to .003
Female .097 .038 to .157
Hypertension .031 2.019 to .081
Diabetes .043 2.007 to .093
Hyperlipidemia 2.007 2.059 to .045
Smoking .084 .022 to .146
Heart disease .036 2.072 to .143
Cilostazol 2.050 2.098 to .002
ARB .008 2.043 to .058
ACE-I .038 2.080 to .156
CCB 2.041 2.091 to .010
Statin .026 2.030 to .082
Change of LDL-C .000 .000 to .001
Change of HDL-C .001 2.002 to .003
Initial CIMT-ave 2.041 2.237 to .155
Abbreviations: ARB, angiotensin-II receptor blocker; ACE-I, angiotens
confidence interval; CIMT, carotid intima–media thickness; HDL-C, hig
cholesterol.
Factors with potential association (P , .20) from the univariate analysi
*Adjusted b and adjusted P represents the results of multivariate analysby multivariate linear regression analysis and by AN-
COVA. The other factors associated with CIMT prog-
ression were sex, diabetes, and smoking. Our results
correspond well with those of the earlier retrospective
study which reported that cilostazol is more beneficial
than other antiplatelets on the regression of CIMT in
ischemic stroke patients.10 Compared with the previous
study, we have strengthened the results by performing ated with CIMT-ave progression
P Adjusted b* Adjusted P*
.38
.002 .098 ,.001
.22
.09 .046 .03
.78
.009 .065 .02
.51
.04 2.046 .03
.77
.52
.11
.36
.27
.55
.68
in converting enzyme inhibitor; CCB, calcium channel blocker; CI,
h-density lipoprotein cholesterol; LDL-C, low-density lipoprotein
s was entered into the multiple regression analysis.
is.
EFFECT OF CILOSTAZOL ON CIMT 1169well-organized randomized controlled trial and by re-
cruiting subjects from multiple centers.
The protocol of our study included aggressive use of
lipid-lowering agents, except for the subjects with unusu-
ally low LDL-C, and therefore, more than half of the pa-
tients received statin. The proportion of patients using
statin was not different between both groups in our re-
sults. However, because of the high proportion of statin
therapy in both groups, the effect of statin on CIMT pro-
gression may have been underestimated. In our results,
cilostazol demonstrated a significant reduction in the
levels of Apo B and Apo B/Apo A1 ratio compared
with clopidogrel. Apo B/Apo A1 ratio, which reflects
the balance between pro-atherogenic particles and anti-
atherogenic particles, is strongly associated with the pro-
gression of CIMT, independent to other lipid profiles.11
Cilostazol effectively changes the lipid profile by
reducing the level of LDL-C and raising the level of
HDL-C.12 Therefore, the anti-atherogenic effect of cilosta-
zol on CIMT may be associated with the changes in lipid
profiles. However, as cilostazol demonstrates pleiotropic
effects—by inhibiting platelet aggregation and prolifera-
tion of vascular smooth muscle cells,13 by suppressing
modified LDL-C uptake and foam cell formations,14 by
improving endothelial cell function and vasodilator func-
tion,15 and by decreasing the expression of adhesion
molecules, inflammatory cells, and cytokines16—other
mechanisms may also be associated with the anti-
atherogenic effect. From a previous trial, the beneficial
effects of cilostazol on CIMTwere still observed after ad-
justing for the changes of lipid profiles.17 According to
our results, although the lipid profiles changed positively
toward preventing the progression of atherosclerosis in
the cilostazol group, the changes of lipid profiles were
not associated with CIMT change. Therefore, cilostazol
may demonstrate an anti-atherogenic effect independent
to the improvements of lipid profiles.
Medical treatment still remains to be the standard treat-
ment of ICAS, and the prevalence of tandem atheroscle-
rotic lesion involving intracranial arteries and carotid
arteries is higher than expected.18 Therefore, there is al-
ways a concern about the response of atherosclerosis in
the carotid artery, when treating ICAS with medical treat-
ment. Additionally, as the significant association between
ischemic stroke and CIMT is not restricted to a specific
subtype of stroke mechanism,19 CIMT must be consid-
ered in treating all subtypes of ischemic stroke including
ICAS. As our results demonstrated the effectiveness of cil-
ostazol on CIMT in symptomatic ICAS patients, the treat-
ment can be more focused on the target site when treating
symptomatic ICAS, though the patients are accompanied
with an increased CIMT.
Increased CIMT proved to be a significant determinant
of long-term functional outcome in ischemic stroke pa-
tients.20 CIMT was also associated with the severity of
cognitive impairment after acute ischemic stroke.21 There-fore, CIMT is valuable for predicting the long-term prog-
nosis in ischemic stroke patients. Cilostazol demonstrated
an anti-atherogenic effect superior to other antiplatelet
agents in the era of stroke. This broad anti-atherogenic
effect of cilostazol in cerebral arteries may contribute to
the effective secondary stroke prevention,22 increased
regional cerebral blood flow, and preserved cognitive
functions.23
However, there are some noteworthy limitations in our
study. First, the subject number included in this study
was small. Because the participation of centers was deter-
mined according to the feasibility, and the substudy was
proposed during the main trial, the number of subjects
with available baseline CIMT was small. However, the
results demonstrate a significant difference in CIMT
changes between cilostazol and control. Second, measure-
ment of CIMTcan be influenced by the ultrasound setting,
the measuring site, and the angle at which CIMTwas as-
sessed. Because this study was performed as a multi-
center study, there can be some intercenter differences.
However, to minimize the intercenter difference, we
have measured CIMT according to a well-organized pro-
tocol based on Mannheim carotid intima-media thickness
consensus and analyzed using semiautomated software.
There was no significant difference in the change of
CIMT between the centers (Supplemental Table 1).
In conclusion, cilostazol may have beneficial effects on
preventing progression of CIMT and improving pro-
atherogenic lipid profiles in symptomatic ICAS patients.
Therefore, the anti-atherogenic effect of cilostazol in ICAS,
which was demonstrated by the main study, may be ex-
tended to the extracranial atherosclerosis by this substudy.Supplementary Data
Supplementary data related to this article can be found
at http://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2013.
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